Attenuated reoviruses for selection of cell populations
AssigneeVirocure, Inc.
InventorsManbok Kim, Derrick E. Rancourt, Nicole Zur Nieden, Randal N. Johnston
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.
Claims21
A method of killing or removing a neoplastic cell from a cellular composition suspected of containing such neoplastic cells comprising contacting the cellular composition with an attenuated reovirus under conditions which result in oncolysis or killing of the neoplastic cell, wherein the attenuated reovirus is a human reovirus and wherein the attenuated reovirus is S1 attenuated reovirus possessing a S1 gene which produces a truncated S1 gene product.
A method of killing or removing a neoplastic cell from a cellular composition suspected of containing such neoplastic cells comprising contacting the cellular composition with an attenuated reovirus under conditions which result in oncolysis or killing of the neoplastic cell, wherein the cellular composition comprises stem cells and wherein the attenuated reovirus is S1 attenuated reovirus possessing a S1 gene which produces a truncated S1 gene product.
A method of killing or removing a neoplastic cell from a cellular composition suspected of containing such neoplastic cells comprising contacting the cellular composition with an attenuated reovirus under conditions which result in oncolysis or killing of the neoplastic cell, wherein the method further comprises contacting the attenuated reovirus-treated cellular composition with an anti-reovirus antibody, N-benzyloxycarbonyl-Phe-Ala-fluoromethylketone (Z-FA-FMK), an RNA-directed RNA polymerase inhibitor, or an antiviral agent, and wherein the attenuated reovirus is S1 attenuated reovirus possessing a S1 gene which produces a truncated S1 gene product.
A method of killing or removing a neoplastic cell from a cellular composition suspected of containing such neoplastic cells comprising contacting the cellular composition with an attenuated reovirus under conditions which result in oncolysis or killing of the neoplastic cell, further comprising transplanting or implanting the attenuated reovirus-treated cellular composition into a recipient, wherein the attenuated reovirus is S1 attenuated reovirus possessing a S1 gene which produces a truncated S1 gene product.
Dependencies are inferred from the claim text.